Champions Oncology

Champions Oncology, AstraZeneca collaborate

Tuesday, August 22, 2017

Champions Oncology, a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, announced a strategic collaboration with AstraZeneca to develop novel cohorts of PDX models. These models will be used in AstraZeneca’s oncology R&D programs in breast and lung cancer, in addition to being added to Champions’ existing TumorGraft bank for translational oncology research for academic and industry customers. Champions’ global network of collaborating sites will be leveraged to support this multi-year initiative.

[Read More]

Champions Oncology, Addario Lung Cancer Medical Institute partner

Friday, August 18, 2017

Champions Oncology, a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, announced a collaboration with The Addario Lung Cancer Medical Institute (ALCMI) to develop a novel cohort of PDX models in patients with ROS1 gene rearrangement. These models will further expand Champions’ TumorGraft bank offerings in non-small cell lung cancer for translational oncology research for academic and industry customers. Champions’ global infrastructure will be leveraged to support this multi-year program.

[Read More]

Champions Oncology to open new lab facility in Maryland

Friday, March 17, 2017

Champions Oncology, a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, has announced plans for opening a new lab facility in Rockville, Maryland, during the second quarter of its 2018 fiscal year. At current levels of business, the company expects to realize a 10% reduction in lab costs.

[Read More]